MX2022004311A - Estirpes celulares de mamiferos con deficiencia de lipasa/esterasa modificadas geneticamente de manera recombinante. - Google Patents

Estirpes celulares de mamiferos con deficiencia de lipasa/esterasa modificadas geneticamente de manera recombinante.

Info

Publication number
MX2022004311A
MX2022004311A MX2022004311A MX2022004311A MX2022004311A MX 2022004311 A MX2022004311 A MX 2022004311A MX 2022004311 A MX2022004311 A MX 2022004311A MX 2022004311 A MX2022004311 A MX 2022004311A MX 2022004311 A MX2022004311 A MX 2022004311A
Authority
MX
Mexico
Prior art keywords
cell lines
mammalian cell
esterase
lipase
recombinantly engineered
Prior art date
Application number
MX2022004311A
Other languages
English (en)
Inventor
Christopher Carl Frye
Stephanie Lynn Sandefur
Troii Hall
Lihua Huang
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2022004311A publication Critical patent/MX2022004311A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01004—Phospholipase A2 (3.1.1.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01034—Lipoprotein lipase (3.1.1.34)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/02—Thioester hydrolases (3.1.2)
    • C12Y301/02022—Palmitoyl-protein hydrolase (3.1.2.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04004—Phospholipase D (3.1.4.4)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01013—Sterol esterase (3.1.1.13)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se proporcionan estirpes celulares de mamíferos con expresión y/o actividad reducida de lipasas/esterasas, y métodos para producirlas. También se proporcionan composiciones que comprenden polisorbato y proteínas recombinantes producidas en dichas células de mamífero que tienen una estabilidad de polisorbato mejorada.
MX2022004311A 2019-10-15 2020-10-14 Estirpes celulares de mamiferos con deficiencia de lipasa/esterasa modificadas geneticamente de manera recombinante. MX2022004311A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962915234P 2019-10-15 2019-10-15
PCT/US2020/055572 WO2021076620A1 (en) 2019-10-15 2020-10-14 Recombinantly engineered, lipase/esterase-deficient mammalian cell lines

Publications (1)

Publication Number Publication Date
MX2022004311A true MX2022004311A (es) 2022-05-10

Family

ID=73139438

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004311A MX2022004311A (es) 2019-10-15 2020-10-14 Estirpes celulares de mamiferos con deficiencia de lipasa/esterasa modificadas geneticamente de manera recombinante.

Country Status (10)

Country Link
US (1) US20220251172A1 (es)
EP (1) EP4045641A1 (es)
JP (1) JP2022552323A (es)
KR (1) KR20220054689A (es)
CN (1) CN114555792A (es)
AU (1) AU2020368369A1 (es)
CA (1) CA3154522A1 (es)
IL (1) IL291599A (es)
MX (1) MX2022004311A (es)
WO (1) WO2021076620A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115315512A (zh) * 2020-03-26 2022-11-08 基因泰克公司 具有降低的宿主细胞蛋白质的经修饰的哺乳动物细胞
CN115989416A (zh) * 2020-08-31 2023-04-18 基因泰克公司 用于评估生物制药开发过程中聚山梨醇酯降解风险的高通量、基于荧光的酯酶活性测定法
CN113155823A (zh) * 2021-05-21 2021-07-23 上海药明生物技术有限公司 表征宿主细胞蛋白中酯酶对聚山梨酯降解活性的方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL151378A0 (en) 2000-02-24 2003-04-10 Univ Washington Humanized antibodies that sequester amyloid beta peptide
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
PT1916001E (pt) 2002-03-04 2011-07-18 Imclone Llc Anticorpos humanos específicos para kdr e suas utilizações
ZA200504866B (en) 2002-12-24 2006-11-29 Rinat Neuroscience Corp Anti-ngf antibodies and methods using same
AU2004251145C1 (en) 2003-06-12 2011-04-14 Eli Lilly And Company GLP-1 analog fusion proteins
PT2805728T (pt) 2003-12-23 2020-04-08 Genentech Inc Novos anticorpos anti-il13 e o uso dos mesmos
ES2387809T3 (es) 2004-03-19 2012-10-02 Imclone Llc Anticuerpo frente al receptor del factor de crecimiento epidérmico humano
JP2009501141A (ja) 2005-06-17 2009-01-15 イムクローン システムズ インコーポレイテッド 転移性骨癌の治療のための受容体アンタゴニスト
HUE039353T2 (hu) 2005-12-13 2018-12-28 Lilly Co Eli Anti-IL-17 ellenanyagok
JO3330B1 (ar) 2010-06-10 2019-03-13 Lilly Co Eli الأجسام المضادة cgrp
EP3042917B1 (en) 2010-08-12 2018-02-21 Eli Lilly and Company Anti-n3pglu amyloid beta peptide antibodies and uses thereof
AR085484A1 (es) 2011-04-06 2013-10-02 Lilly Co Eli ANTICUERPOS QUE SE UNEN A TGF-a Y EPIREGULINA
TWI636063B (zh) 2013-03-08 2018-09-21 美國禮來大藥廠 結合ｉｌ－２３之抗體
TWI612059B (zh) 2013-03-15 2018-01-21 美國禮來大藥廠 泛－ＥＬＲ<sup>＋</sup>ＣＸＣ趨化因子抗體
US9932591B2 (en) 2013-12-18 2018-04-03 University Of Delaware Reduction of lipase activity in product formulations
AR100270A1 (es) 2014-05-19 2016-09-21 Lilly Co Eli Anticuerpos ang2
JO3576B1 (ar) 2015-02-26 2020-07-05 Lilly Co Eli أجسام مضادة لـ tau واستخداماتها
TW201702380A (zh) 2015-02-27 2017-01-16 再生元醫藥公司 宿主細胞蛋白質修飾
AR105616A1 (es) 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
CN108138147B (zh) 2015-09-22 2022-11-01 豪夫迈·罗氏有限公司 含Fc蛋白的表达
WO2018039499A1 (en) * 2016-08-24 2018-03-01 Regeneron Pharmaceuticals, Inc. Host cell protein modification
JOP20190093A1 (ar) 2016-10-28 2019-04-25 Lilly Co Eli أجسام مضادة لـ il-33 واستخداماتها
JOP20190261A1 (ar) 2017-05-19 2019-11-05 Lilly Co Eli أجسام مضادة لعامل مساعد لـ btla واستخداماتها
AR112341A1 (es) 2017-08-02 2019-10-16 Lilly Co Eli ANTICUERPOS BIESPECÍFICOS ANTI-TNF- / ANTI-IL-23 DE IgG
AR113022A1 (es) 2017-09-29 2020-01-15 Lilly Co Eli Anticuerpo anti-pacap
WO2019136300A2 (en) 2018-01-05 2019-07-11 Immunext, Inc. Anti-mct1 antibodies and uses thereof
TWI724392B (zh) 2018-04-06 2021-04-11 美商美國禮來大藥廠 生長分化因子15促效劑化合物及其使用方法
TWI728400B (zh) 2018-07-26 2021-05-21 美商美國禮來大藥廠 Cd226促效劑抗體
TWI749367B (zh) 2018-09-14 2021-12-11 美商美國禮來大藥廠 Cd200r促效劑抗體及其用途
TWI734279B (zh) 2018-12-14 2021-07-21 美商美國禮來大藥廠 抗α-突觸核蛋白抗體及其用途
EP3899485A4 (en) 2018-12-18 2022-10-05 UT-Battelle, LLC RAPID NATIVE SINGLE CELL MASS SPECTROMETRY

Also Published As

Publication number Publication date
KR20220054689A (ko) 2022-05-03
IL291599A (en) 2022-05-01
JP2022552323A (ja) 2022-12-15
EP4045641A1 (en) 2022-08-24
WO2021076620A1 (en) 2021-04-22
CA3154522A1 (en) 2021-04-22
CN114555792A (zh) 2022-05-27
US20220251172A1 (en) 2022-08-11
AU2020368369A1 (en) 2022-05-12

Similar Documents

Publication Publication Date Title
MX2022004311A (es) Estirpes celulares de mamiferos con deficiencia de lipasa/esterasa modificadas geneticamente de manera recombinante.
BR112018009161A2 (pt) limitação da trealose produzida por levedura em fermentação
MX2021013380A (es) Proteinas policlonales recombinantes y metodos de uso de las mismas.
WO2017075389A8 (en) Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells
WO2020102503A8 (en) Fusosome compositions for t cell delivery
MX2021008142A (es) Metodos para cosechar cultivos de celulas de mamifero.
MX2020004541A (es) Edicion de genes de celulas primarias.
WO2021092581A9 (en) Generation of engineered regulatory t cells
MX2013005853A (es) Enzimas de fusion que tienen actividad de n-acetilglucosaminil transferasa.
MX2018011276A (es) Regulación del sistema de señalizacion ras/camp/pka en levaduras.
MX2021006783A (es) Transposasa de piggybac mutada.
BR112021021777A2 (pt) Métodos para a produção de ergotioneína
AR103794A1 (es) Producción de alquenos
WO2021195464A3 (en) Modified mammalian cells having reduced host cell proteins
MX2023009756A (es) Variantes de amilasa.
MX2022010654A (es) Metodos para reducir la degradacion de polisorbato en formulaciones farmacologicas.
WO2019121961A3 (en) Methods for modulating protein mannosylation profiles using maduramycin, narasin, or salinomycin
MX2022006994A (es) Metodos para generar celulas madre hematopoyeticas.
MX2023002411A (es) Celulas inmunitarias modificadas para fibrosis e inflamacion.
EA201170025A1 (ru) Способы повышения жизнеспособности и продукции культуры клеток
WO2022016166A3 (en) Differentiation of trophectoderm lineage cells from pluripotent stem cells
CA3156678A1 (en) CELLS WITH SUSTAINED TRANSGENIC EXPRESSION
WO2021026506A3 (en) Aminoacyl-trna synthetases and cell lines for site-specific incorporation of unnatural amino acids
MX2021008983A (es) Atributos de aflibercept y metodos de caracterizacion y modificacion de los mismos.
MX350005B (es) Microorganismos fermentadores de pentosa.